Boustany Johnny, Abdessater Maher, Hachem Charbel El, Khoury Ziad El, Khoury Walid El, Khoury Raghid El
Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon.
Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon.
Oncotarget. 2020 May 19;11(20):1922-1928. doi: 10.18632/oncotarget.27543.
Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy. The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib. Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life. Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach.
伴有肉瘤样去分化的肾细胞癌是肾细胞癌的一种类型，它经历了间变转化，同时具有癌性和肉瘤性成分。转移性患者的标准治疗方法是免疫疗法。本文的目的是描述我们对一名59岁男性转移性复发性肾细胞癌伴肉瘤样去分化患者的治疗情况，该患者接受了肾切除术和多次转移灶切除术，随后使用卡博替尼治疗。连续的PET-CT扫描显示，在最后一次转移灶切除术后三年没有复发迹象，患者目前生活正常。肉瘤样去分化仍然是肾细胞癌预后不良的因素。对于转移性年轻患者，转移灶手术切除后使用卡博替尼可能是一种治疗选择。然而，前瞻性随机试验将是验证这种方法的最佳选择。
